Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial by Capasso, Immacolata et al.
TRIALS
Capasso et al. Trials 2013, 14:273
http://www.trialsjournal.com/content/14/1/273RESEARCH Open AccessCombination of inositol and alpha lipoic acid
in metabolic syndrome-affected women:
a randomized placebo-controlled trial
Immacolata Capasso1*, Emanuela Esposito1, Nicola Maurea2, Maurizio Montella3, Anna Crispo3,
Michelino De Laurentiis1, Massimiliano D’Aiuto1, Giuseppe Frasci1, Gerardo Botti6, Maria Grimaldi3,
Ernesta Cavalcanti4, Giuseppe Esposito5, Alfredo Fucito1, Giuseppe Brillante1, Giuseppe D’Aiuto1
and Gennaro Ciliberto1Abstract
Background: Inositol has been reported to improve insulin sensitivity since it works as a second messenger achieving
insulin-like effects on metabolic enzymes. The aim of this study was to evaluate the inositol and alpha lipoic acid
combination effectiveness on metabolic syndrome features in postmenopausal women at risk of breast cancer.
Methods: A six-month prospective, randomized placebo-controlled trial was carried out on a total of 155
postmenopausal women affected by metabolic syndrome at risk of breast cancer, the INOSIDEX trial. All women
were asked to follow a low-calorie diet and were assigned randomly to daily consumption of a combination of
inositol and alpha lipoic acid (77 pts) or placebo (78 pts) for six months. Primary outcomes we wanted to achieve
were both reduction of more than 20% of the HOMA-IR index and of triglycerides serum levels. Secondary
outcomes expected were both the improvement of high-density lipoprotein cholesterol levels and the reduction
of anthropometric features such as body mass index and waist-hip ratio.
Results: A significant HOMA-IR reduction of more than 20% was evidenced in 66.7% (P <0.0001) of patients,
associated with a serum insulin level decrease in 89.3% (P <0.0000). A decrease in triglycerides was evidenced in
43.2% of patients consuming the supplement (P <0.0001). An increase in HDL cholesterol (48.6%) was found in the
group consuming inositol with respect to the placebo group. A reduction in waist circumference and waist-hip
ratio was found in the treated group with respect to the placebo group.
Conclusions: Inositol combined with alpha lipoic acid can be used as a dietary supplement in insulin-resistant
patients in order to increase their insulin sensitiveness. Daily consumption of inositol combined with alpha lipoic
acid has a significant bearing on metabolic syndrome. As metabolic syndrome is considered a modifiable risk
factor of breast tumorigenesis, further studies are required to assess whether inositol combined with alpha lipoic
acid can be administered as a dietary supplement in breast cancer primary prevention.
Trial registration: Current Controlled Trial ISRCTN74096908.
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Postmenopausal status tends to increase the risk of being
overweight or obese that frequently determines the onset
of metabolic syndrome (MS) [1-5]. MS, according to the
National Cholesterol Education Program (NCEP) Adult
Treatment Panel III (ATP III), can be defined as the
presence of at least three of the following clinical cri-
teria: waist circumference >88 cm in women, high-
density lipoprotein cholesterol (HDL-C) <50 mg/dl, blood
pressure ≥130/85 mmHg, fasting plasma glucose ≥110 mg/dl,
or triglyceride >150 mg/dl [6]. MS affects about 34% of
the general population. Postmenopausal women are often
affected by MS and show the highest incidence of breast
cancer in the female population. Breast cancer is also as-
sociated with adverse outcomes in patients with metabolic
syndrome phenotype [7]. Our previous studies have shown
the strict correlation between metabolic syndrome and
breast cancer on a huge sample of women [1,2]. Results
from those studies reported statistically significant higher
prevalence of metabolic syndrome in breast cancer patients
with respect to healthy ones (35% vs. 19%) after meno-
pause. Moreover insulin resistance has been reported to
greatly contribute to cell growth and breast carcinogenesis
[2,8]. These outcomes allowed us to consider MS, and
particularly insulin resistance, as modifiable risk factors
increasing breast carcinogenesis. Hormonal and meta-
bolic abnormalities may contribute directly or indirectly
to an environment for tumor growth. Recently, it has
been shown that diabetic patients with breast cancer re-
ceiving metformin during neoadjuvant chemotherapy have
higher pathologic complete response rates compared with
diabetics not receiving metformin [8]. Nevertheless, further
studies with larger sample size are needed to assess the
validity of novel strategies both for breast cancer chemo-
prevention and therapy based on targeting insulin signaling
pathways. In most of the cases, we have women affected by
metabolic syndrome with hyperinsulinemia or insulin
resistance but not classical diabetes, and the use of met-
formin is not allowed for this group of patients. Inositol
is a polyalcohol classified as an insulin sensitizer. The
phosphatidylinositol 3-kinase (PI3K)/Akt pathway medi-
ates the effects of a variety of extracellular signals in a
number of cellular processes including cell growth, pro-
liferation, and survival. The alteration of integrants of
this pathway through mutation of its coding genes in-
creases the activation status of the signaling and can
thus lead to cellular transformation. The frequent dys-
regulation of the PI3K/Akt pathway in breast cancer
(BC) and the mediation of this pathway in different pro-
cesses characteristically implicated in tumorigenesis
have attracted the interest of this pathway in BC [9,10].
Inositol has been reported to improve insulin sensitivity
since it works as a second messenger that may achieve an
insulin-like effect on metabolic enzymes [11,12]. Inositolcombined with alpha lipoic acid can be used as a dietary
supplement in insulin-resistant patients in order to in-
crease their insulin sensitiveness. Inositol is a vitamin B
complex constituent that rules as a second messenger in
the insulin pathway. Alpha lipoic acid is a fatty acid that
plays a leading role in the cellular energetic metabolism
exerting antioxidant activities on free radicals, promot-
ing glucose cellular intake, taking part in fat catabolism
on the Krebs cycle. Insulin resistance has demonstrated
to be a keystone ruling as a gonadotropic and antiapoptotic
factor and favoring proinflammatory effects. Furthermore,
alteration in lipid profile tends to interfere with cellular
growth pattern, promoting cellular damage stimulating
free radicals. Alpha lipoic acid strengthens the inositol
effects and acts as an antioxidant agent. The combin-
ation of inositol and alpha lipoic acid may be a useful
supplement to integrate into a regular lifestyle, with a
low-calorie diet, physical activity and clinical/radiological
examination for postmenopausal women who want to
prevent breast cancer and cardiovascular injuries. The
aim of the following study was to evaluate the inositol
and alpha lipoic acid combination effectiveness on meta-
bolic syndrome features in postmenopausal women at risk
of breast cancer by obtaining an optimum control of
insulin resistance and lipid profile.Methods
Study design
We carried out a six-month, prospective, randomized
placebo-controlled trial on a total of 155 postmenopausal
women fulfilling the criteria of metabolic syndrome and
at risk of breast cancer (with a familial history of breast
or ovarian cancer, or women operated on for borderline
lesions such as ductal hyperplasia or papillomatosis). All
women were asked to follow a low-calorie diet and were
randomly assigned to daily consumption of a combin-
ation of inositol and alpha lipoic acid or a placebo for
six months.
The distribution of genetic and predisposing risk factors
of breast cancer was 60% (93 pts) of patients with a famil-
ial history of breast cancer. Some 77% (71 pts) of them
had a positive family history of breast cancer in a first-
degree relative (mother, daughter, or sister), whereas 23%
(22 pts) had a second-degree relative with a familial his-
tory of breast cancer. Some 64% (100 pts) of patients had
a personal history of previous biopsies for borderline
lesions. A total of 95% of women who underwent lumpec-
tomy for borderline lesions had a familial history of breast
cancer. Women were invited to attend a ‘high familial risk
breast screening program’ set up by the National Cancer
Institute. Women aged over forty had a clinical examin-
ation, mammogram and ultrasound. Women under forty
had a clinical examination, ultrasound and MRI when
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at all visits.
Measures and assay methods
In accordance with the Helsinki Declaration of 1975, after
obtaining informed consent from each woman, anthropo-
metric features were measured, including weight in
kilograms, height in meters, waist and hip circumference,
arterial blood pressure was taken and venous blood was
collected on study entry. Body mass index (BMI) (kg/m2)
was calculated from weight and height values and evalu-
ated according to the World Health Organization classi-
fication (<25 kg/m2 = underweight/normal, ≥25 kg/m2 =
overweight/obese). The waist-to-hip ratio (WHR) was
obtained from waist and hip circumference, measuring
the smallest circumference of both to discriminate be-
tween android and gynoid fat distribution. Fasting plasma
glucose, insulin, HDL-C and triglycerides serum levels
were assessed from blood samples. In particular, fasting
plasma glucose, HDL-C and triglycerides were measured
according to the NCEP ATP III criteria. Blood samples
were locally assessed at the central laboratory of the
National Cancer Institute. Sample collection was stan-
dardized by time at the blood withdrawing. Samples were
taken in the early morning hours (between 8.00 and
10.00 am). Fasting plasma glucose assessment was measured
by the COBAS INTEGRA Glucose HK cassette (GLUC2;
Roche, Basel, Switzerland). It contains an in vitro diagnos-
tic reagent system intended for use on COBAS INTEGRA
systems for the quantitative determination of the glucose
concentration in hemolysate. Electrochemiluminescence
immunoassay (ECLIA) applied on Cobas 6000 was used
for insulin concentration measurement. The enzymatic
colorimetric test CHOD-POD was employed for choles-
terol dosage. The GPO-POD method, based on the
enzymatic determination of glycerol, using the enzyme
glycerol phosphate oxidase (GPO), was used for triglycer-
ides determination. Fresh, clear, unhemolyzed serum
was the specimen of choice. The specimen was collected
following the guidelines of NCCLS document H4-A3.
Insulin levels were defined in the normal range when
between 5 and 25 mcU/ml, whereas concentrations above
25 mcU/ml were considered corresponding to hyper-
insulinemia. Insulin resistance was calculated by the homeo-
stasis model assessment ratio-insulin resistance (HOMA-IR).
To define women as positive for MS we adopted the Adult
Treatment Panel III of the National Cholesterol Education
Program criteria. All women presenting at least three
of the five criteria described on ATPIII were consid-
ered affected by metabolic syndrome.
Baseline demographics of patients
A personal health questionnaire was assessed in order to
measure personal health-related quality of life. Womenwere asked to give information about their daily alcohol
intake, smoking, physical activities and sports. A total of
64% of women denied consuming any sort of alcoholic
drink. Likewise 64% of women did not smoke cigarettes.
On the other hand, only 17% of women answered that
they did any physical activity and only 14% declared
doing some sports.Enrollment steps
 Patients were invited to take part in the trial by their
consultants. Women who agreed to take part in the
trial were asked to sign a form. However, signing the
form did not mean that they must remain in the trial.
 After clinical examination was confirmed to be
negative, a mammogram and ultrasound were
performed. Women presenting a positive or
suspicious mammogram and/or ultrasound were
excluded from the trial.
 Anthropometric measures, arterial blood pressure
and venous blood samples were taken
 Patients fulfilling at least three of the five criteria
described on NCEP ATPIII (waist circumference
(WC) >88 cm, HDL-C <50 mg/dl, blood pressure
≥130/85 mmHg, fasting plasma glucose ≥110 mg/dl,
or triglyceride >150 mg/dl) were considered affected
by metabolic syndrome. Patients affected by metabolic
syndrome were considered eligible for enrollment.
 All women were asked to follow a low-calorie diet
and were randomly assigned to daily consumption of
a combination of inositol and alpha lipoic acid (77 pts)
or a placebo (78 pts) for six months. Patients enrolled
were asked to follow the Therapeutic Lifestyle Changes
(TLC) Diet according to the National Cholesterol
Educational Program (NCEP) guidelines. The TLC
eating plan is one that advises less than 7% of calories
from saturated fat and less than 200 mg of dietary
cholesterol per day. There should be no more than 25
to 35% or less of total daily calories coming from total
fat intake. A limit of 2400 mg of day of sodium is
recommended. The TLC diet recommends weight
maintenance and avoidance of weight gain through
caloric homeostasis. Reduction of saturated fat, trans
fat, and cholesterol within the diet is recommended.
Increased consumption of soluble fiber is requested.
 Sample size (ss) was determined using the following
formula [13]
ss ¼ Z
2  pð Þ  1−pð Þ
c2
Where:
Z = Z value (for example 1.96 for 95% confidence level)
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(.5 used for sample size needed)
c = confidence interval, expressed as a decimal
1:962  0:25ð Þ  1−0:25ð Þ
0:0752
Statistical method
Student’s paired t test was used for parametric variables
and the Wilcoxon test for nonparametric variables like
HOMA in order to analyze values at baseline and at the
end point. One-way analysis of variance for parametric
variables and the Kruskal-Wallis test for nonparametric
variables like HOMA were used in order to compare
treatment effects of the two arms. P <0.0005 was consid-
ered statistically significant.
Exclusion criteria
The exclusion criteria were as follows: women presenting
a positive or suspicious mammogram and/or ultrasound;
women not fulfilling at least three of the five criteria of
metabolic syndrome; diabetic women taking oral hypogly-
cemic drugs or insulin injections, diabetes diagnosed after
a blood sample was taken in our institution, and patients
consuming statins for hypercholesterolemia. As diabetes
was considered an exclusion criterion, diabetes was diag-
nosed on laboratory determinations with fasting plasma
glucose assessment ≥126 mg/dl according to American
Diabetes Association guidelines [12]. Fasting plasma glu-
cose levels in the range between 110 and 126 mg/dl were
considered as hyperglycemia.
Ethical considerations
The INOSIDEX trial was approved by the National Cancer
Institute Ethical Committee, protocol number 23/12 OSS
from Register M1/2 - metabolic syndrome, insulinemia,
BMI in breast cancer prevention - a monocentric non-
profit study from the National Cancer Institute of
Naples - principal investigator: Dr. Immacolata Capasso.
The primary investigators ensured that the study was
conducted with full patient compliance, with protocol
regulation conformity as well as international standards
on human subject research. The primary investigators
ensured compliance with institutional regulations as well
as local and national law.
Follow-up phase
This phase comprised of six-monthly visits. Women were
examined by the same doctors at all visits. During each
visit, a clinical examination was performed, anthropomet-
ric features and arterial pressure were measured, blood
samples were taken, dietary questionnaires were compiled
to understand patient compliance to the study. Healthstatus and medication changes were recorded and adverse
events were asked for.
Results
Baseline data
The mean age was 57.71 ± 7.9. At baseline mean BMI
(kg/m2) was 30.35 ± 5.32, mean waist circumference was
97.15 ± 10 cm. Mean WHR was 0.87 ± 0.06. At baseline
there was no difference between the two groups in age,
BMI, WC, HOMA-IR and lipid profile.
Primary outcomes
 Reduction of more than 20% of the HOMA-IR index
 Reduction of triglycerides
Secondary outcomes
 Improvement of HDL-C levels
 Reduction of anthropometric features such as BMI,
WHR
Data analysis
HOMA-IR value total reduction was detected in 86.7%
of patients after six months of treatment with inositol
and alpha lipoic acid. As a primary outcome, a significant
HOMA-IR reduction of more than 20% between baseline
and six-month follow-up was evidenced in 66.7% of
patients in the treatment group, and there was a statis-
tically significant effect of treatment compared to placebo
on HOMA-IR reduction (P <0.0001) (Table 1). Serum
insulin level decrease was detected in 89.3% of patients
consuming the supplement. Wilcoxon test for nonpara-
metric variables confirmed the statistical significant
effect of the treatment (P <0.05). Regarding lipid profile,
significant increase in HDL-C was measured in 48.6%
patients in the group consuming inositol with respect to
the placebo group after six months of treatment (mean
increasing 6%). Reduction in triglycerides (mean 4.9%)
was also evidenced in the treated group in 43.2% pts
(P <0.0001). A little reduction, nonstatistically significant
was observed in HOMA-IR, BMI and WC in the placebo
group thanks to the low-calorie diet alone. Good control
of metabolic syndrome was helped by diet results with
the insulin-sensitizing supplements and the related pri-
mary prevention of breast cancer. No adverse effects were
registered. Good patient compliance and adherence was
obtained. All women enrolled in the trial completed it
successfully.
Discussion
Clinical considerations
MS, characterized by abdominal obesity, high blood glu-
cose levels, impaired glucose tolerance, dyslipidemia, and
Table 1 Anthropometric and metabolic features of the study groups: inositol + alpha lipoic acid (n = 77), placebo (n = 78)
Ino + α T0 Plac T0 Ino + α T6 Plac T6 Ino + α vs Pla P T0 Ino + α vs Pla P T6 P Ino + α T0 vs T6 P Plac T0 vs T6
Age 57.71 ± 7.9 58.2 ± 5.6
BMI, kg/m2 30.35 ± 5.3 29.21 ± 4.8 28.46 ± 6.2 28.34 ± 5.7 0.1 0.7 <0.0001 0.002
WC cm 97.15 ± 10 99.23 ± 8 92.34 ± 9 97 ± 7 0.08 0.1 <0.000 0.0001
WHR 0.87 ± 0.06 0.89 ± 0.02 0.79 ± 0.04 0.81 ± 0.03 0.1 <0.0001 <0.000 0.0001
Glucose, mg/dl 106 ± 19.58 107 ± 20.13 95 ± 21.56 102 ± 21.79 0.64 <0.0001 <0.000 0.03
Insulin, mmol/L 15.53 ± 8.08 13.74 ± 7.04 8.51 ± 5.11 11.98 ± 6.88 <0.0001 <0.0001 <0.000 0.08
HOMA-IR 4.06 ± 2.44 4.02 ± 1.61 2.74 ± 1.53 3.99 ± 1.22 0.0001 <0.0001 <0.000 0.01
HDL-C, mg/dl 42.30 ± 13.42 40.46 ± 12.45 48.80 ± 14.79 41.72 ± 15.13 0.8 <0.0001 <0.000 0.9
Chol-tot mg/dl 214.63 ± 42.56 203.08 ± 32.71 202.92 ± 49.72 202.01 ± 30.51 0.2 <0.0001 <0.0001 0.3
Triglycerides, mg/dl 111.18 ± 46 112.23 ± 49 90.37 ± 34.36 109.78 ± 48 <0.0001 <0.0001 <0.0001 0.4
Values are means ± SD. Ino + α, inositol plus alpha lipoic acid; T0, time 0; Plac, placebo; T6, 6 months; P, P value. BMI, body mass index; WC, waist circumference; WHR, waist-hip ratio; HOMA-IR homeostasis model
assessment ratio-insulin resistance; HDL-C, high-density lipoprotein cholesterol; Chol-tot, total cholesterol; SD, standard deviation.
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http://www.trialsjournal.com/content/14/1/273hypertension, is associated with increased risk of type 2
diabetes and coronary heart disease. Several studies have
examined the association of the individual components of
MS with BC; to date, however, no study has assessed MS
per se in relation to BC risk. Furthermore, previous studies
have relied only on baseline assessment of components of
the syndrome [5]. Nevertheless, a crucial role is supposed
to be played by the altered insulin signaling, occurring in
obese/overweight patients, which fuels cancer cell growth,
proliferation and survival [2]. Insulin resistance is mea-
sured through the HOMA-IR score. The cutoff value to
define insulin resistance was HOMA-IR ≥2.50. Higher
prevalence of MS (35%) was found among postmenopausal
women with BC compared to postmenopausal healthy
women (19%) (odds ratio 2.16) in our previous study
[2]. Visceral adipose tissue has multiple endocrine, meta-
bolic and immunological functions and has been shown
to be central in MS pathogenesis [1,2]. Consistent with
this, obesity and insulin resistance are supposed to be
modifiable risk factors for BC [14,15]. Inositol has been
reported to improve insulin sensitivity since it works
as a second messenger that may achieve an insulin-
like effect on metabolic enzymes [11,12]. Inositol com-
bined with alpha lipoic acid can be used as a dietary
supplement in insulin-resistant patients in order to in-
crease their insulin sensitiveness. After only six months of
treatment with inositol and alpha lipoic acid, combined
with a low-calorie diet, postmenopausal women at risk of
BC showed significant reduction in HOMA-IR score and
lipid profile control with respect to the placebo group.
The data of the present study seems to indicate that
MS, particularly insulin resistance, in the postmeno-
pausal population, may be ameliorated by insulin-sensitizing
supplementation. As a secondary outcome, we can consider
good metabolic control as a useful means in all hormone-
related cancer prevention programs, including BC, among
postmenopausal women.
Conclusions
Interestingly, outcomes from our study show that inositol
improves insulin sensitivity since it works as a second
messenger achieving an insulin-like effect on metabolic
enzymes. Inositol combined with alpha lipoic acid can be
used as a dietary supplement in insulin-resistant patients
not consuming oral hypoglycemic drugs, in order to in-
crease their insulin sensitiveness. The primary end point
of our study was to determine the HOMA-IR reduction
of more than 20% in patients consuming inositol with
respect to the placebo group. A significant HOMA-IR
reduction of more than 20% was evidenced in 66.7%
(P <0.0001) for the treated group of patients. Serum insu-
lin decreasing levels were detected in 89.3% of patients
consuming the supplement with inositol. According to
the lipid profile, reduction in triglycerides (−43.2%) wasevidenced in the treated group (P <0.0001). Significant
increase in HDL-C (48.6%) was found in the group con-
suming inositol with respect to the placebo group. Post-
menopausal women affected by MS show the highest
incidence of BC in the female population. A certain
correlation between MS and BC incidence has been
widely highlighted in the worldwide literature and MS
is now considered a modifiable risk factor of BC. Based
on these findings, postmenopausal women affected by
MS can easily consume, without any side effects, inosi-
tol and alpha lipoic acid as a daily dietary supplement,
combined with a low-calorie diet, to reduce insulin resist-
ance and increase HDL-C. MS control can be considered
as a first step forward for BC primary prevention.
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